“What makes I-O transformative?” Innovative approaches in patient selection, use of combinations, and sequencing of therapies lead to more patients benefitting from I-O therapy, expanding its potential impact and this also makes it more promising- from the basics of immunotherapies to the latest research results. The rapid development of immuno-oncology (I-O) therapies has transformed the treatment landscape and brightened the long-term outlook for many patients with advanced cancer.

Following the exceptional success of 2 editions in the USA and 4 editions in the UK, MarketsandMarkets is proud to announce the 3rd Annual Next Gen Immuno-Oncology Congress to be held on 25th and 26th June 2020 in Boston, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, monoclonal antibody & Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, brain-storming on cancer biomarker and vaccine research, collaborating on pre-clinical and translational immune-oncology developments, and personalized cancer immunotherapy.